Your browser doesn't support javascript.
loading
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Madhi, Shabir A; Moodley, Dhayendre; Hanley, Sherika; Archary, Moherndran; Hoosain, Zaheer; Lalloo, Umesh; Louw, Cheryl; Fairlie, Lee; Fouche, Leon Frederik; Masilela, Mduduzi S L; Singh, Nishanta; Grobbelaar, Coert; Ahmed, Khatija; Benadé, Gabriella; Bhikha, Sutika; Bhorat, As'ad Ebrahim; Bhorat, Qasim; Joseph, Natasha; Dheda, Keertan; Esmail, Aliasgar; Foulkes, Sharne; Goga, Ameena; Oommen Jose, Aylin; Kruger, Gertruida; Kalonji, Dishiki J; Lalloo, Natasha; Lombaard, Johan J; Lombard Koen, Anthonet; Kany Luabeya, Angelique; Mngqibisa, Rosie; Petrick, Friedrich G; Pitsi, Annah; Tameris, Michele; Thombrayil, Asha; Vollgraaff, Pieter-Louis; Cloney-Clark, Shane; Zhu, Mingzhu; Bennett, Chijioke; Albert, Gary; Faust, Emmanuel; Plested, Joyce S; Fries, Lou; Robertson, Andreana; Neal, Susan; Cho, Iksung; Glenn, Greg M; Shinde, Vivek.
Afiliação
  • Madhi SA; Vaccines and Infectious Diseases Analytics Research Unit, South African Medical Research Council, University of the Witwatersrand, Johannesburg, South Africa; African Leadership in Vaccinology Expertise, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: shabir.madhi@wi
  • Moodley D; Department of Obstetrics and Gynaecology, University of KwaZulu-Natal, Durban, South Africa.
  • Hanley S; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
  • Archary M; Enhancing Care Foundation, Durban, South Africa.
  • Hoosain Z; Josha Research Centre, Bloemfontein, South Africa.
  • Lalloo U; Respiratory and Critical Care Unit, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Louw C; Madibeng Centre for Research, Department of Family Medicine, University of Pretoria, Pretoria, South Africa.
  • Fairlie L; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
  • Fouche LF; Limpopo Clinical Research Initiative, Thabazimbi, South Africa.
  • Masilela MSL; Setshaba Research Centre, Tshwane, South Africa.
  • Singh N; HIV Prevention Research Unit, South African Medical Research Council, Verulam and Isipingo Clinical Research Site, Durban, South Africa.
  • Grobbelaar C; Aurum Institute, University of Pretoria, Pretoria, South Africa.
  • Ahmed K; Department of Microbiology, University of Pretoria, Pretoria, South Africa; Setshaba Research Centre, Tshwane, South Africa.
  • Benadé G; Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
  • Bhikha S; Vaccines and Infectious Diseases Analytics Research Unit, South African Medical Research Council, University of the Witwatersrand, Johannesburg, South Africa.
  • Bhorat AE; Soweto Clinical Trials Centre, Johannesburg, South Africa.
  • Bhorat Q; Soweto Clinical Trials Centre, Johannesburg, South Africa.
  • Joseph N; MERC Research, Kempton Park, South Africa.
  • Dheda K; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, Cape Town, South Africa; Faculty of Infectious and Tropical Diseases, Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK
  • Esmail A; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, Cape Town, South Africa.
  • Foulkes S; Josha Research Centre, Bloemfontein, South Africa.
  • Goga A; Health Systems Research Unit and HIV Prevention Research Unit, South African Medical Research Council, Cape Town, South Africa.
  • Oommen Jose A; Vaccines and Infectious Diseases Analytics Research Unit, South African Medical Research Council, University of the Witwatersrand, Johannesburg, South Africa.
  • Kruger G; MERC Research, Middelburg, South Africa.
  • Kalonji DJ; HIV Prevention Research Unit, South Africa Medical Research Council, Isipingo, South Africa.
  • Lalloo N; Respiratory and Critical Care Unit, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • Lombaard JJ; Josha Research Centre, Bloemfontein, South Africa.
  • Lombard Koen A; Vaccines and Infectious Diseases Analytics Research Unit, South African Medical Research Council, University of the Witwatersrand, Johannesburg, South Africa.
  • Kany Luabeya A; HIV Prevention Research Unit, South African Medical Research Council, Verulam and Isipingo Clinical Research Site, Durban, South Africa.
  • Mngqibisa R; Enhancing Care Foundation, Durban, South Africa.
  • Petrick FG; MERC Research, Middelburg, South Africa.
  • Pitsi A; Setshaba Research Centre, Tshwane, South Africa.
  • Tameris M; HIV Prevention Research Unit, South African Medical Research Council, Verulam and Isipingo Clinical Research Site, Durban, South Africa.
  • Thombrayil A; Vaccines and Infectious Diseases Analytics Research Unit, South African Medical Research Council, University of the Witwatersrand, Johannesburg, South Africa.
  • Vollgraaff PL; Limpopo Clinical Research Initiative, Thabazimbi, South Africa.
  • Cloney-Clark S; Novavax, Gaithersburg, MD, USA.
  • Zhu M; Novavax, Gaithersburg, MD, USA.
  • Bennett C; Novavax, Gaithersburg, MD, USA.
  • Albert G; Novavax, Gaithersburg, MD, USA.
  • Faust E; Novavax, Gaithersburg, MD, USA.
  • Plested JS; Novavax, Gaithersburg, MD, USA.
  • Fries L; Novavax, Gaithersburg, MD, USA.
  • Robertson A; Novavax, Gaithersburg, MD, USA.
  • Neal S; Novavax, Gaithersburg, MD, USA.
  • Cho I; Novavax, Gaithersburg, MD, USA.
  • Glenn GM; Novavax, Gaithersburg, MD, USA.
  • Shinde V; Novavax, Gaithersburg, MD, USA.
Lancet HIV ; 9(5): e309-e322, 2022 05.
Article em En | MEDLINE | ID: mdl-35489376
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_aids / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases Assunto principal: Vacinas Virais / Infecções por HIV / HIV-1 / Soropositividade para HIV / Nanopartículas / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Lancet HIV Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_aids / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases Assunto principal: Vacinas Virais / Infecções por HIV / HIV-1 / Soropositividade para HIV / Nanopartículas / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Lancet HIV Ano de publicação: 2022 Tipo de documento: Article